Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 95225-95226 [2024-28147]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 231 / Monday, December 2, 2024 / Notices
covers a portion of the possible
applications of E–046–2022.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 25, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–28081 Filed 11–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:25 Nov 29, 2024
Jkt 265001
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
95225
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid effective
October 10, 2023 (88 FR 70814), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Dynacare *, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories Approved
to Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on
urine specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823. (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
E:\FR\FM\02DEN1.SGM
02DEN1
ddrumheller on DSK120RN23PROD with NOTICES1
95226
Federal Register / Vol. 89, No. 231 / Monday, December 2, 2024 / Notices
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130. (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917.
Desert Tox, LLC, 5425 E Bell Rd., Suite
125, Scottsdale, AZ 85254, 602–457–
5411/623–748–5045.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
Dynacare *, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630. (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Laboratory Corporation of America,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295.
(Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984.
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group), Laboratory Corporation
of America Holdings, 1120 Main
Street, Southaven, MS 38671, 866–
827–8042/800–233–6339. (Formerly:
LabCorp Occupational Testing
Services, Inc.; MedExpress/National
Laboratory Center)
MedTox Laboratories, Inc., 402 W
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
VerDate Sep<11>2014
18:25 Nov 29, 2024
Jkt 265001
2088. Testing for Veterans Affairs
(VA) Employees Only.
Omega Laboratories, Inc.*, 2150
Dunwin Drive, Unit 1 & 2,
Mississauga, ON, Canada L5L 5M8,
289–919–3188.
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840.
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085. Testing for
Department of Defense (DoD)
Employees Only
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories continued under
DOT authority. The responsibility for
conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory as meeting
the minimum standards of the current
Mandatory Guidelines published in the
Federal Register. After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program. DOT established this process
in July 1996 (61 FR 37015) to allow
foreign laboratories to participate in the
DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace
Programs.
[FR Doc. 2024–28147 Filed 11–29–24; 8:45 am]
BILLING CODE 4160–20–P
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
0361.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: 988 Suicide & Crisis
Lifeline and Crisis Services Program
Evaluation—New Package
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) 988 & Behavioral Health
Crisis Coordinating Office (BHCCO)) is
requesting clearance for the new data
collection associated with the
evaluation of the SAMHSA 988 Suicide
and Crisis Lifeline and Crisis Services
Program Evaluation (988 Suicide and
Crisis Lifeline Evaluation). The
collection of this information is critical
to successfully oversee operational
response and quality of service through
the 988 Suicide and Crisis Lifeline to
ensure connections to care for
individuals in suicidal crisis or
emotional distress contacting in for 988
phone, chat, and text support for
connecting local, state/territory, and
national outcomes and monitoring
contractual obligations for current and
future 988 Suicide and Crisis Lifeline
grant programs. Much of the
information is already embedded in the
current 988 Suicide and Crisis Lifeline
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 89, Number 231 (Monday, December 2, 2024)]
[Notices]
[Pages 95225-95226]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-28147]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-2600 (voice);
[email protected] (email).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) publishes a notice listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities (IITFs) in the Federal Register
during the first week of each month, in accordance with section 9.19 of
the Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any laboratory or IITF certification is
suspended or revoked, the laboratory or IITF will be omitted from
subsequent lists until such time as it is restored to full
certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/drug-testing-resources/certified-lab-list.
HHS separately notifies Federal agencies of the laboratories and
IITFs currently certified to meet the standards of the Mandatory
Guidelines using Urine and of the laboratories currently certified to
meet the standards of the Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23, 2017 (82 FR 7920); and on October
12, 2023 (88 FR 70768).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020, and subsequently revised in the
Federal Register on October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for Federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid
effective October 10, 2023 (88 FR 70814), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved To
Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare *, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190, (Formerly: Gamma-Dynacare Medical Laboratories).
HHS-Certified Laboratories Approved to Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on urine specimens:
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823. (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
[[Page 95226]]
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130. (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917.
Desert Tox, LLC, 5425 E Bell Rd., Suite 125, Scottsdale, AZ 85254, 602-
457-5411/623-748-5045.
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890.
Dynacare *, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630. (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609.
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295. (Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.
CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group), Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only.
Omega Laboratories, Inc.*, 2150 Dunwin Drive, Unit 1 & 2, Mississauga,
ON, Canada L5L 5M8, 289-919-3188.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085. Testing for
Department of Defense (DoD) Employees Only
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories continued under DOT authority.
The responsibility for conducting quarterly performance testing plus
periodic on-site inspections of those LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS' NLCP contractor continuing
to have an active role in the performance testing and laboratory
inspection processes. Other Canadian laboratories wishing to be
considered for the NLCP may apply directly to the NLCP contractor just
as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory as meeting the minimum
standards of the current Mandatory Guidelines published in the Federal
Register. After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program. DOT
established this process in July 1996 (61 FR 37015) to allow foreign
laboratories to participate in the DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-28147 Filed 11-29-24; 8:45 am]
BILLING CODE 4160-20-P
